Oculis (OCS) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free OCS Stock Alerts $12.02 -0.14 (-1.15%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 6:29 AM | marketbeat.comOculis Holding AG (NASDAQ:OCS) to Post Q2 2024 Earnings of ($0.42) Per Share, HC Wainwright ForecastsOculis Holding AG (NASDAQ:OCS - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2024 EPS estimates for shares of Oculis in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earningsMay 15 at 6:12 AM | americanbankingnews.comFY2025 Earnings Estimate for Oculis Holding AG Issued By HC Wainwright (NASDAQ:OCS)May 15 at 3:08 AM | americanbankingnews.comOculis (NASDAQ:OCS) Stock Rating Reaffirmed by HC WainwrightMay 14 at 11:10 AM | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Oculis Holding (OCS)May 14 at 8:54 AM | marketbeat.comBrokers Offer Predictions for Oculis Holding AG's FY2025 Earnings (NASDAQ:OCS)Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Oculis in a report issued on Monday, May 13th. HC Wainwright analyst Y. Chen expects that the company will earn ($1.62) per share for the year.May 13 at 8:20 AM | marketbeat.comOculis' (OCS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 price target on shares of Oculis in a research note on Monday.May 8, 2024 | markets.businessinsider.comOculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic NeuritisMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 7, 2024 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingMay 6, 2024 | globenewswire.comOculis to Present at Bank of America Global Healthcare ConferenceApril 30, 2024 | marketbeat.comOculis (NASDAQ:OCS) Sees Large Volume IncreaseOculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeApril 29, 2024 | marketbeat.comOculis (NASDAQ:OCS) Stock Price Up 8.3%Oculis (NASDAQ:OCS) Shares Up 8.3%April 29, 2024 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingApril 28, 2024 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Short Interest Down 21.0% in AprilOculis Holding AG (NASDAQ:OCS - Get Free Report) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 25,600 shares, a decline of 21.0% from the March 31st total of 32,400 shares. Based on an average daily volume of 51,100 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the company's stock are sold short.April 26, 2024 | investing.comOculis shares target cut, retains buy rating on completed equity financingApril 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Oculis Holding Ahead of Key OCS-02 Drug Data ReleaseApril 26, 2024 | marketbeat.comOculis Holding AG to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:OCS)Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at HC Wainwright raised their Q2 2024 earnings estimates for Oculis in a research report issued on Wednesday, April 24th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.37) per shareApril 25, 2024 | marketbeat.comabrdn plc Acquires Shares of 1,452,741 Oculis Holding AG (NASDAQ:OCS)abrdn plc purchased a new stake in Oculis Holding AG (NASDAQ:OCS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,452,741 shares of the company's stock, valued at approximately $15,980,000. abrdn plc owned approximately 3.9April 24, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)April 24, 2024 | marketbeat.comOculis (NASDAQ:OCS) Price Target Lowered to $28.00 at HC WainwrightHC Wainwright lowered their price target on Oculis from $29.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday.April 22, 2024 | finanznachrichten.deOculis Holding AG: Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 22, 2024 | globenewswire.comOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 22, 2024 | globenewswire.comOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 12, 2024 | marketbeat.comShort Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 31.4%Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 32,400 shares, a decrease of 31.4% from the March 15th total of 47,200 shares. Approximately 0.2% of the company's stock are short sold. Based on an average trading volume of 37,700 shares, the short-interest ratio is currently 0.9 days.April 11, 2024 | globenewswire.comOculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main MarketApril 10, 2024 | globenewswire.comOculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & DevelopmentApril 9, 2024 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Buy" by BrokeragesOculis Holding AG (NASDAQ:OCS - Get Free Report) has received an average rating of "Buy" from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts thApril 8, 2024 | globenewswire.comPositive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingApril 4, 2024 | globenewswire.comOculis to Participate at Upcoming April Investor ConferencesMarch 25, 2024 | msn.comOculis Holding (NASDAQ:OCS): Riding on Bullish ExpectationsMarch 22, 2024 | marketbeat.comLeerink Partnrs Comments on Oculis Holding AG's Q1 2024 Earnings (NASDAQ:OCS)Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Oculis in a research note issued on Wednesday, March 20th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earningsMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed on Oculis Holding with Promising Clinical Pipeline and Strong Financial PositionMarch 19, 2024 | marketbeat.comOculis (NASDAQ:OCS) Stock Rating Reaffirmed by Chardan CapitalChardan Capital restated a "buy" rating and issued a $30.00 price objective on shares of Oculis in a report on Tuesday.March 19, 2024 | marketbeat.comOculis (NASDAQ:OCS) PT Lowered to $35.00 at Robert W. BairdRobert W. Baird reduced their price target on shares of Oculis from $64.00 to $35.00 and set an "outperform" rating on the stock in a research report on Tuesday.March 18, 2024 | finanznachrichten.deOculis Holding AG: Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company ProgressMarch 18, 2024 | globenewswire.comOculis Reports Q4 and Full Year 2023 Financial Results and Update on Company ProgressMarch 15, 2024 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Given Average Rating of "Buy" by AnalystsOculis Holding AG (NASDAQ:OCS - Get Free Report) has been assigned an average rating of "Buy" from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month target price amoMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed: Oculis Holding’s Promising Ophthalmic Therapies Poised for Market ImpactMarch 1, 2024 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Sees Large Drop in Short InterestOculis Holding AG (NASDAQ:OCS - Get Free Report) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 22,200 shares, a decrease of 41.3% from the January 31st total of 37,800 shares. Currently, 0.1% of the company's stock are sold short. Based on an average trading volume of 38,700 shares, the days-to-cover ratio is currently 0.6 days.March 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Oculis Holding (OCS)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oculis Holding on Promising DME and DED Drug ProspectsFebruary 29, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Oculis Holding Amid Promising Clinical Trials and Market PotentialFebruary 29, 2024 | marketbeat.comOculis (NASDAQ:OCS) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $29.00 price target on shares of Oculis in a research report on Thursday.February 28, 2024 | globenewswire.comOculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership AppointmentsFebruary 25, 2024 | marketbeat.comNan Fung Group Holdings Ltd Reduces Stake in Oculis Holding AG (NASDAQ:OCS)Nan Fung Group Holdings Ltd lessened its stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) by 6.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 606,684 shares of the company's stock afterFebruary 19, 2024 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Given Average Rating of "Buy" by BrokeragesOculis Holding AG (NASDAQ:OCS - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are covering the company, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covereFebruary 17, 2024 | marketbeat.comOculis (NASDAQ:OCS) Stock Price Up 0.4%Oculis (NASDAQ:OCS) Trading 0.4% HigherFebruary 1, 2024 | finance.yahoo.comHow Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%January 29, 2024 | finance.yahoo.comWhat Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing' Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address [URGENT] DO NOT Touch These AI Stocks! (Ad)Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over? Click here for our #1 AI Stock for 2024 and Beyond OCS Media Mentions By Week OCS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCS News Sentiment▼0.160.55▲Average Medical News Sentiment OCS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCS Articles This Week▼132▲OCS Articles Average Week Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: STTK News Today TVTX News Today KALV News Today ALT News Today VERV News Today LRMR News Today ANL News Today CMPS News Today ABUS News Today ATXS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
